About Us

We are building and advancing a portfolio through global approval by establishing strong ties and collaborations with endocrinologists, the medical community at large and patient advocacy organizations worldwide.

Our goal is to provide physicians with new therapeutic strategies to improve the lives of their patients with rare endocrine and related diseases. Currently, our development pipeline includes two therapeutic peptide programs: AZP-3601 for the treatment of hypoparathyroidism and AZP-3813 for the treatment of acromegaly. Simultaneously, we continue to build our pipeline and have an on-going research program for a novel therapeutic peptide candidate, AZP-3404. We also continuously look for external innovation in rare endocrine and related diseases.

Our global management team is composed of a highly dedicated group of senior executives with proven drug development, registration and commercialization, and achievements in peptide therapeutics, as well as thorough knowledge of rare endocrine and related disease.

We are supported by an impressive board of directors and strong international syndicate of investors, as well as a robust IP portfolio and key academic collaborations.

LEADERSHIP

Management

Our global management team is composed of a highly dedicated group of senior executives with proven drug development expertise and achievements in peptide therapeutics, as well as thorough knowledge of rare endocrine and metabolic disorders.

Thiery Abribat
Thierry Abribat, Ph.D.

Founder and Chief Executive Officer

Louis J. Arcudi III

Chief Financial Officer

Michael Culler
Michael Culler, Ph.D.

Chief Scientific Officer

Patrick Loustau
Patrick Loustau, M.S., M.A.

Chief Business Officer

Soraya Allas
Soraya Allas, M.D., PH.D.

VP, Clinical Development and Regulatory Affairs

Delphine Martinez
Delphine Martinez

General Counsel

Thomas Delale, Ph.D.
Thomas Delale, Ph.D.

VP, Portfolio Management

David Duracher, Ph.D.

VP, Chemistry Manufacturing and Control

Bénédicte Gagnere
Bénédicte Gagnere, M.S.

Head of Finance

Board OF DIRECTORS
Pierre Legault

Chairman of the Board of Directors

James Hindman

Chair of the Audit and Compensation Committees

Elisabeth Svanberg

Independent Director

Felice Verduyn-van Weegen

Partner, LSP

Naveed Siddiqi

Partner, Novo Ventures

Thierry Laugel

Managing Partner, Kurma Partners

Raphaël Wisniewski

Partner, Andrea Partners

Stefan Larson, Ph.D.

Partner, Sectoral Asset Management

Thierry Abribat

CEO, Amolyt Pharma

Investors

Since its inception through series B financing, Amolyt Pharma, has raised 105 M€ (~$120 M) from a strong international syndicate of investors.

Scientific and Medical Advisors
David Clemmons
David Clemmons, M.D.

University of North Carolina

Aart Jan (AJ) Van Der Lely, M.D., Ph.D.
Aart Jan (AJ) van der Lely, M.D., Ph.D.

Erasmus University Medical Center

AZP-3601: Clinical Advisory Board
JOHN BILEZIKIAN
John Bilezikian, M.D.

College of Physicians & Surgeons, Columbia University

MARIA LUISA BRANDI
Maria Luisa Brandi, M.D.

University of Florence

BART L. CLARKE, M.D​
Bart L. Clarke, M.D

Mayo Clinic

Aliya Khan, M.D.
Aliya Khan, M.D.

McMaster University

Michael Mannstadt
Michael Mannstadt, M.D.

Massachusetts General Hospital and Harvard Medical School

Lars Rejnmark, M.D.
Lars Rejnmark, M.D.

Aarhus University

Scroll to Top